Merion Robert M, Pelletier Shawn J, Goodrich Nathan, Englesbe Michael J, Delmonico Francis L
Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA.
Ann Surg. 2006 Oct;244(4):555-62. doi: 10.1097/01.sla.0000239006.33633.39.
This study examines donation after cardiac death (DCD) practices and outcomes in liver transplantation.
Livers procured from DCD donors have recently been used to increase the number of deceased donors and bridge the gap between limited organ supply and the pool of waiting list candidates. Comprehensive evaluation of this practice and its outcomes has not been previously reported.
A national cohort of all DCD and donation after brain-death (DBD) liver transplants between January 1, 2000 and December 31, 2004 was identified in the Scientific Registry of Transplant Recipients. Time to graft failure (including death) was modeled by Cox regression, adjusted for relevant donor and recipient characteristics.
DCD livers were used for 472 (2%) of 24,070 transplants. Annual DCD liver activity increased from 39 in 2000 to 176 in 2004. The adjusted relative risk of DCD graft failure was 85% higher than for DBD grafts (relative risk, 1.85; 95% confidence interval, 1.51-2.26; P < 0.001), corresponding to 3-month, 1-year, and 3-year graft survival rates of 83.0%, 70.1%, and 60.5%, respectively (vs. 89.2%, 83.0%, and 75.0% for DBD recipients). There was no significant association between transplant program DCD liver transplant volume and graft outcome.
The annual number of DCD livers used for transplant has increased rapidly. However, DCD livers are associated with a significantly increased risk of graft failure unrelated to modifiable donor or recipient factors. Appropriate recipients for DCD livers have not been fully characterized and recipient informed consent should be obtained before use of these organs.
本研究探讨心脏死亡后器官捐献(DCD)在肝移植中的应用情况及结果。
最近,来自DCD供体的肝脏已被用于增加已故供体的数量,并缩小有限的器官供应与等待名单候选人库之间的差距。此前尚未有对这种做法及其结果的综合评估报告。
在移植受者科学登记处确定了2000年1月1日至2004年12月31日期间所有DCD和脑死亡后器官捐献(DBD)肝移植的全国队列。通过Cox回归对移植失败时间(包括死亡)进行建模,并对相关供体和受体特征进行调整。
在24,070例移植中,472例(2%)使用了DCD肝脏。DCD肝脏的年度使用量从2000年的39例增加到2004年的176例。DCD移植失败的校正相对风险比DBD移植高85%(相对风险,1.85;95%置信区间,1.51 - 2.26;P < 0.001),对应的3个月、1年和3年移植存活率分别为83.0%、70.1%和60.5%(而DBD受者分别为89.2%、83.0%和75.0%)。移植项目的DCD肝移植量与移植结果之间无显著关联。
用于移植的DCD肝脏年度数量迅速增加。然而,DCD肝脏与移植失败风险显著增加相关,且与可改变的供体或受体因素无关。DCD肝脏的合适受者尚未完全明确,在使用这些器官之前应获得受者的知情同意。